<DOC>
	<DOCNO>NCT00010010</DOCNO>
	<brief_summary>RATIONALE : Estrogen stimulate growth breast cancer cell . Hormone therapy use exemestane plus goserelin may fight breast cancer reduce production estrogen . PURPOSE : Phase II trial study effectiveness exemestane goserelin treat premenopausal woman metastatic breast cancer respond previous tamoxifen .</brief_summary>
	<brief_title>Exemestane Plus Goserelin Treating Premenopausal Women With Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine efficacy exemestane goserelin premenopausal woman hormone receptor positive metastatic breast cancer tamoxifen failure . II . Determine toxicity regimen patient . III . Determine hormonal profile patient treat regimen . IV . Determine predictive value HER-2 , epidermal growth factor receptor , estrogen receptor response patient treat regimen . OUTLINE : Patients receive oral exemestane daily day 1-28 goserelin subcutaneously day 1 . Treatment repeat every 28 day absence disease progression unacceptable toxicity . PROJECTED ACCRUAL : A total 22-40 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Goserelin</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm metastatic breast cancer fail prior tamoxifen therapy Measurable disease No CNS metastases Hormone receptor status : Estrogen progesterone receptor positive At least 10 fmol/L biochemical assay OR At least 10 % cell positive immunochemistry PATIENT CHARACTERISTICS : Age : 18 Sex : Female Menopausal status : Premenopausal define estradiol least 30 pg/mL , follicle stimulate hormone less 25 mIU/mL , luteinizing hormone less 15 mIU/mL Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,000/mm3 Platelet count least 50,000/mm3 Hepatic : Bilirubin great 2.0 mg/dL AST great 3 time normal Renal : Stable renal function Pulmonary : No pulmonary embolism Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective nonhormonal contraception 12 week study No prior malignancy except nonmelanoma skin cancer carcinoma situ cervix No known hypersensitivity luteinizing hormone release hormone ( LHRH ) , LHRH agonist analogue , component goserelin PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No 2 prior chemotherapy regimen Endocrine therapy : See Disease Characteristics No prior hormonal therapy metastatic breast cancer No concurrent estrogen ( hormone replacement ) therapy No concurrent hormonal agent breast cancer ( e.g. , tamoxifen , anastrozole , letrozole , aminoglutethimide , megestrol ) No concurrent corticosteroid breast cancer unless already receive therapy study entry Radiotherapy : Not specify Surgery : Not specify Other : Concurrent bisphosphonates allow bone disease provide measurable disease nonosseous sit No concurrent anticoagulant therapy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
</DOC>